Equities research analysts forecast that Mesoblast limited (NASDAQ:MESO) will post $6.36 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Mesoblast’s earnings, with estimates ranging from $1.61 million to $11.10 million. Mesoblast reported sales of $13.40 million during the same quarter last year, which indicates a negative year-over-year growth rate of 52.5%. The business is scheduled to issue its next earnings results on Tuesday, February 26th.
According to Zacks, analysts expect that Mesoblast will report full year sales of $16.58 million for the current year, with estimates ranging from $6.80 million to $25.50 million. For the next year, analysts forecast that the company will post sales of $48.44 million, with estimates ranging from $11.20 million to $85.67 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Mesoblast.
Mesoblast (NASDAQ:MESO) last issued its earnings results on Thursday, November 15th. The company reported ($0.20) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.04. Mesoblast had a negative net margin of 171.79% and a negative return on equity of 12.90%. The firm had revenue of $11.64 million during the quarter, compared to the consensus estimate of $1.03 million.
A number of research analysts recently weighed in on MESO shares. HC Wainwright set a $17.00 target price on shares of Mesoblast and gave the company a “buy” rating in a research report on Thursday, October 25th. Maxim Group reiterated a “buy” rating and issued a $16.00 price objective on shares of Mesoblast in a research note on Monday, November 12th. Cantor Fitzgerald set a $23.00 target price on shares of Mesoblast and gave the company a “buy” rating in a report on Sunday, November 11th. Oppenheimer set a $15.00 price target on shares of Mesoblast and gave the company a “buy” rating in a report on Monday, November 12th. Finally, ValuEngine downgraded shares of Mesoblast from a “buy” rating to a “hold” rating in a research report on Tuesday, December 18th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $11.92.
Several institutional investors have recently added to or reduced their stakes in the stock. Penbrook Management LLC lifted its position in shares of Mesoblast by 6.2% during the 4th quarter. Penbrook Management LLC now owns 240,900 shares of the company’s stock valued at $993,000 after acquiring an additional 14,000 shares during the period. Jane Street Group LLC acquired a new position in shares of Mesoblast during the 3rd quarter valued at $117,000. Capital World Investors acquired a new position in shares of Mesoblast during the 3rd quarter valued at $3,695,000. Renaissance Technologies LLC lifted its position in shares of Mesoblast by 249.8% during the 3rd quarter. Renaissance Technologies LLC now owns 165,161 shares of the company’s stock valued at $1,348,000 after acquiring an additional 117,951 shares during the period. Finally, Citadel Advisors LLC acquired a new position in shares of Mesoblast during the 3rd quarter valued at $215,000. Institutional investors own 3.01% of the company’s stock.
Shares of MESO stock traded up $0.04 during trading hours on Wednesday, hitting $4.31. 37,970 shares of the company were exchanged, compared to its average volume of 36,903. The company has a quick ratio of 3.57, a current ratio of 3.57 and a debt-to-equity ratio of 0.12. Mesoblast has a 52 week low of $3.35 and a 52 week high of $8.78. The company has a market capitalization of $402.11 million, a price-to-earnings ratio of -6.84 and a beta of 1.74.
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
Further Reading: Quick Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.